Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 16/20 | 0.42 |
| ▸ | RXRB | P28702 | 2/20 | 0.42 |
| ▸ | RXRG | P48443 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3202677 | 0.93 | HDAC6 (0.36) | RXRARXRBRXRGHDAC6ALDH1A1 | |
| SCHEMBL3210241 | 0.91 | RXRA (0.39) | RXRARXRBRXRGHDAC6P2RX3 | |
| SCHEMBL3126412 | 0.90 | TSHR (0.42) | HDAC6MAPTALDH1A1MAPK1 | |
| SCHEMBL3126325 | 0.89 | RXRA (0.38) | RXRARXRBRXRGHDAC6P2RX3 | |
| SCHEMBL3120590 | 0.88 | LMNA (0.38) | RXRARXRBRXRGHDAC6MAPT | |
| SCHEMBL3212923 | 0.88 | MAPK1 (0.39) | HDAC6MAPTALDH1A1MAPK1 | |
| SCHEMBL3128439 | 0.88 | RXRA (0.55) | RXRARXRBRXRGPPARG | |
| SCHEMBL3202834 | 0.87 | RXRA (0.40) | RXRARXRBRXRGHDAC6PPARG | |
| SCHEMBL3120270 | 0.85 | PDE4A (0.38) | RXRARXRBRXRGHDAC6MAPT | |
| SCHEMBL3218540 | 0.83 | RXRA (0.40) | RXRARXRBRXRGHDAC6PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE3B | RXRA 2856/4885RXRB 2676/4885RXRG 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.